Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (161-170 of 224) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patientsLaura Mansi, Laurie Spehner, Etienne Daguindau, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Clinical Breast Cancer|July 7, 2024
Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast CancerAntoine El Kaddissi, Dewi Vernerey, Antoine Falcoz, et al.
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
Journal of the National Cancer Institute|April 7, 2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic AdenocarcinomaAngélique Vienot, Guillaume Beinse, Christophe Louvet, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
The Journal of Infection|August 28, 2020
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severityMarie Kroemer, Laurie Spehner, Lucie Vettoretti, et al.
Frontiers in Oncology|September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinomaStefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
The Lancet. Oncology|November 22, 2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialJaafar Bennouna, Javier Sastre, Dirk Arnold, et al.
Pageof 23

Showing results (161-170 of 224) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patientsLaura Mansi, Laurie Spehner, Etienne Daguindau, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Clinical Breast Cancer|July 7, 2024
Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast CancerAntoine El Kaddissi, Dewi Vernerey, Antoine Falcoz, et al.
JAMA Oncology|June 18, 2025
Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors: A Secondary Analysis of the SAMCO-PRODIGE 54 Randomized Clinical TrialJulien Taïeb, Francesco Giulio Sullo, Aurélie Lecanu, et al.
Journal of the National Cancer Institute|April 7, 2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic AdenocarcinomaAngélique Vienot, Guillaume Beinse, Christophe Louvet, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
The Journal of Infection|August 28, 2020
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severityMarie Kroemer, Laurie Spehner, Lucie Vettoretti, et al.
Frontiers in Oncology|September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinomaStefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|April 30, 2017
Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effectsSimon Pernot, Cecile Badoual, Magali Terme, et al.
The Lancet. Oncology|November 22, 2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialJaafar Bennouna, Javier Sastre, Dirk Arnold, et al.
Pageof 23